Cephalon's $125M Antitrust Deal Is Valid, Atty Power Unknown
A contract outlining terms of Cephalon Inc.'s $125 million settlement, which resolved allegations it paid competitors to delay generic versions of its Provigil drug, is binding and enforceable, a Pennsylvania federal...To view the full article, register now.
Already a subscriber? Click here to view full article